BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open: first published as 10.1136/bmjopen-2019-032918 on 8 March 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

BMJ Open

AN OBSERVATIONAL PROSPECTIVE STUDY PROTOCOL TO DESIGN NEW DIAGNOSTIC SYSTEMS FOR THE EARLY DETECTION OF TOBACCO-ASSOCIATED CHRONIC RENAL DAMAGE.

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2019-032918
Article Type:	Protocol
Date Submitted by the Author:	11-Jul-2019
Complete List of Authors:	Prieto, Marta; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy Vicente-Vicente, Laura; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy Casanova, Alfredo G; ibsal Hernández-Sánchez, M Teresa; ibsal Gomez-Marcos, Manuel; ibsal, ; ibsal, Garcia-Ortiz, Luis; La Alamedilla health centre. University of Salamanca, Primary care research unit La Alamedilla Morales, Ana Isabel; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy;
Keywords:	tobacco, kidney damage, biomarkers

SCHOLARONE™
Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2019-032918 on 8 March 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

For peer review only

AN OBSERVATIONAL PROSPECTIVE STUDY PROTOCOL TO DESIGN NEW DIAGNOSTIC SYSTEMS FOR THE EARLY DETECTION OF TOBACCO-ASSOCIATED CHRONIC RENAL DAMAGE.

Marta Prieto[1,2,3], Laura Vicente-Vicente[1,2,3], Alfredo G Casanova[1,2,3], M Teresa Hernández-Sánchez[1,2,3], Manuel A Gomez-Marcos[2,4,5], Luis Garcia-Ortiz[2,4,6], Ana I Morales[1,2,3]

[1] Toxicology Unit, University of Salamanca, Salamanca, Spain

[2] Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

[3] Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), Salamanca, Spain.

[4] Primary Health Care Research Unit, La Alamedilla Health Center, Health Service of Castilla y León (SACyL),Salamanca, Spain

[5] Department of Medicine, University of Salamanca, Salamanca, Spain

[6] Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain

Corresponding Author:

Ana I Morales

Postal address: Postal Edificio Departamental, Lab 223, Campus Miguel de Unamuno, 37007 Salamanca, Spain

e-mail: amorales@usal.es

Telephone number: +34

Word count: 3956

For peer review only

ABSTRACT

Introduction: Tobacco causes kidney damage that can degenerate into chronic kidney disease in the long term. However, the diagnostic parameters used in the clinic are not effective at identifying smokers most at risk.

Our first objective is to more effectively detect subclinical renal damage in smokers. In addition, we hypothesize that tobacco consumption can predispose smokers to renal damage on exposure to other potentially nephrotoxic events, (pharmacological treatments, diagnostic procedures etc.). We will test this hypothesis in our 2nd objective by investigating whether certain predisposition markers (GM2AP, Transferrin, and t-Gelsolin) are able to detect smokers who are predisposed to kidney damage. Finally (objective 3), we will study whether smoking cessation reduces subclinical and/or predisposition to renal damage.

Methods and analysis: For objective 1, a prospective cross-sectional study will be carried out with patients from a Primary Healthcare Centre. The influence of tobacco on renal damage, in patients both with and without additional risk factors, will be studied using a panel of early biomarkers (albuminuria, NAG, KIM-1, and NGAL). Objective 2 will be carried out through a prospective longitudinal study with the patients recruited in objective 1. We will study whether certain predisposition biomarkers (GM2AP, Transferrin, and t-Gelsolin) are able to detect smokers who are predisposed to renal damage. For objective 3, a prospective longitudinal study will be carried out with patients from a Smoking Cessation Unit. We will study the evolution of the markers described above following smoking cessation.

Ethics and dissemination: The study has been approved by the Clinical Research Ethics Committee of the Healthcare Area of Salamanca. All study participants will sign an informed consent form in compliance with the Declaration of Helsinki and the WHO standards for observational studies. Results will be presented at conferences and submitted to peer-reviewed journals.

Trial Registration number: NCT03850756

Keywords: Tobacco, kidney damage, biomarkers

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- In order to study the influence of tobacco on kidney damage, four groups of patients will be established: smokers and non-smokers, both with and without risk factors associated with kidney damage.
- We will study the relationship between smoking and urinary biomarkers of early kidney damage (albuminuria, NAG, KIM-1, and NGAL).
- We will analyze whether the predisposition/sensitization markers previously described in our laboratory are able to predict renal damage in smokers, in the medium term.
- We will test whether smoking cessation reduces subclinical renal damage and/or the risk of acute renal damage by analyzing the evolution of early damage and predisposition markers, respectively.

For peer review only

INTRODUCTION

Tobacco is one of the greatest threats to public health that the world has had to face. According to World Health Organization (WHO), smoking is the leading cause of preventable disease and death, and a major risk factor for the development of various respiratory and cardiovascular diseases, as well as cancer. It is the only product of legal consumption that harms all those exposed, being the cause of death of almost 6 million people a year, of which over 5 million are direct consumers, and over 600,000 are non-smokers exposed to second-hand smoke.[1]

Despite the fact that the first associations between smoking and kidney disease date back to the beginning of the last century, the evidence has so far been scarce, and inconclusive for those without kidney disease-associated risk factors. One of the first studies was "The Multiple Risk Factor Intervention Trial" (MRFIT) which observed that smoking was associated with terminal kidney disease in a dose-dependent manner.[2] Later, the study by Pinto-Sietsma et al. ,[3] "Prevention of Renal and Vascular Endstage Disease" (PREVEND), revealed a possible relationship between the number of cigarettes consumed per day and the prevalence of microalbuminuria, a marker of incipient renal damage. It was concluded that those who smoked more than 20 cigarettes per day had higher levels of microalbuminuria than non-smokers without additional risk factors, such as diabetes mellitus or high blood pressure. In addition, studies conducted with hypertensive patients have reported that the prevalence of microalbuminuria is almost doubled in smokers compared to non-smokers, and hypertensive patients who smoke more than 20 cigarettes per day have a prevalence of microalbuminuria 1.6 times higher.[4] In diabetes patients, it seems that the additional risk factor of smoking is related to an increase in microalbuminuria, which in turn produces an increased risk of developing proteinuria and accelerating the progression of kidney damage.[5] A large cohort study conducted in 2016 [6] found that smoking is associated with a high glomerular filtration rate, and a high prevalence of proteinuria, suggesting a mechanism of hyperfiltration that could progress to chronic kidney disease.

The increase in the worldwide prevalence of chronic kidney disease and the notable increase in the incidence of patients reaching the final stages [7] have alerted the health systems to invest more in the identification of potentially modifiable prevention factors.[8] Chronic kidney disease has a very high social and economic cost (almost 10% of the affected population and 3% of total health expenditure), which requires coordinated criteria among health professionals to ensure the highest quality in prevention, diagnosis, and treatment.[9] In addition, the identification of kidney disease as a cardiovascular risk factor, and the high morbidity and mortality associated with it, highlight the need for preventive strategies in potentially avoidable factors, such as tobacco use.[10]

For peer review only

It is recognized that the key to preventive success is very early diagnosis, allowing intervention while the renal functional reserve has not yet been exhausted and, therefore, the excretory function is not yet compromised.[11] In the clinic, one of the most common diagnostic tools for kidney damage is the detection of metabolic products (for example creatinine and urea), which accumulate in the blood once the renal excretory capacity begins to decrease. However, at the stage when serum urea and creatinine levels are detectably increased, more than 70% of renal function has already been lost. Thus, there is a current trend in diagnostics to identify sensitive, specific, and easily quantifiable markers that detect incipient pathophysiological events in the early stages, when the damage is less widespread.[12] These potential markers may, for example, be involved in the synthesis, activation, or inhibition of biochemical process mediators and cellular structural constituents related to processes such as apoptosis and tissue regeneration. Likewise, signs of destruction of tissues (extracellular matrix, and basal membranes) could be found in the urine, whether they are whole or degraded molecules, or remnants of organelles, cells, or tissues. The urinary detection of certain cellular enzymes associated with renal cell injury is currently the procedure for the early detection of the tubular subtype of kidney damage. In this sense, urinary detection of the enzyme N-acetyl-beta-d-glucosaminidase (NAG) represents one of the finest techniques for the detection of tubular damage, although it is not established as a standard diagnostic technique.[13] Other markers, such as protein kidney damage molecule 1 (KIM-1), or lipocalin associated with neutrophil gelatinase (NGAL), are in an advanced stage of clinical development as early urinary markers of kidney damage.[14]

Our hypothesis is that some of these early markers could detect the subclinical renal damage caused by tobacco.

Based on this hypothesis, we set the following objectives: (Objective 1) To detect subclinical renal damage in smokers through a panel of early markers (albuminuria, NAG, KIM-1, and NGAL); (Objective 2) To study whether certain predisposition markers previously identified in our group (Ganglioside GM2 activator protein (GM2AP), transferrin, and t-Gelsolin), can detect those smokers who are predisposed to acute kidney injury; and (Objective 3) To study whether smoking cessation reduces subclinical renal damage and/or predisposition to acute kidney injury.

To this end, a consortium of researchers and clinicians has been created, consisting of: 1) experts in markers of kidney damage, 2) clinical specialists in lifestyles and cardiovascular risk, and 3) specialists in smoking cessation.

For peer review only

METHODS AND ANALYSIS

Study design

For the development of this project, 3 studies are proposed, each related to an objective (see Figure 1):

Objective 1. A prospective cross-sectional study is proposed to evaluate the usefulness of early markers in the diagnosis of renal damage associated with tobacco use. Four groups of patients will be established (Table 1) that will allow us to study the influence of tobacco on kidney damage, both in patients with and without risk factors.

Group	Smoker*	Risk factors**
1	-	-
2	-	X
3	X	-
4	X	X

Table 1. Groups of patients established in the study design. *Any person who habitually consumes tobacco at the time of sample collection or ceased smoking during the last year will be considered a smoker (see section "Collection and processing of urine samples").[15] **The following factors involved in the development of kidney damage will be considered risk factors: diabetes mellitus, hypertension, and/or frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs; more than three days a week during the three months prior to sampling).

Objective 2. A longitudinal prospective study is proposed to evaluate the usefulness of predisposition markers of predisposition to acute kidney injury in the context of the smoking patient. Patients from groups 1 and 3 (non-smokers and smokers without other risk factors that may influence predisposition, respectively) of objective 1 will be studied (see Table 1).

Objective 3. A prospective longitudinal study is proposed to evaluate whether the risk of renal damage decreases with the cessation of tobacco consumption. This will involve follow-up of patients from the Tabaquic Detoxification Unit of the University Hospital of Salamanca.

Sample size

The sample size has been estimated on the basis of detection of differences in the parameters analyzed between the four groups defined in objective 1. As information on the variability of microalbuminuria is available from previous studies of the population, this parameter has been used for the estimation. Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral

For peer review only

contrast, 120 subjects in each group are required to detect a minimum difference of 18 mg/g of the albumin/creatinine index between two of the four groups, considering a common standard deviation of 40 mg/g. Each group has been increased by 5 subjects to account for possible losses due to technical issues, meaning that a total of 500 subjects will be recruited (125 per group). Using the same criterion, the number of patients needed for objective 3 has been estimated as 100.

Subjects of study

Objective 1. Patients of legal age from the "La Alamedilla" Health Center of Salamanca (Spain) will be included. A total of 500 patients will be recruited (125 per group). During the recruitment process we will ensure that there are no significant differences in terms of gender and age between the groups.

Objective 2. A follow-up of 200 smoking patients recruited in the previous objective will be carried out, specifically 100 each from groups 1 and 3. This sample size has been estimated allowing for the possibility that some patients from objective 1 are unwilling or unable to participate in the study of objective 2.

Objective 3. We will recruit 100 patients who start treatment in the Tabaquic Detoxification Unit of the University Hospital of Salamanca.

Inclusion criteria

Patients of legal age who agree to participate in the study, sign the informed consent, meet the inclusion criteria previously specified for each group, and do not meet any of the exclusion criteria.

Exclusion criteria

Patients who are terminally ill, have previously been diagnosed with renal failure, do not wish to sign the informed consent, or have been treated with any of the following drugs during the week prior to, or at the time of, sample collection: aminoglycosides, cephalosporins, tetracyclines, amphotericin B, cisplatin, cyclosporine, foscarnet, acyclovir, cidofovir, radiological contrasts, or any other potentially nephrotoxic drugs.

Specific variables

Objective 1. We will analyze the presence of biomarkers of early kidney damage (albuminuria, NAG, KIM-1, and NGAL) at the time of patient recruitment. We will study the association of these markers with tobacco consumption with respect to the presence or absence of other risk factors for kidney damage.

For peer review only

Objective 2. We will analyze markers of predisposition to acute kidney injury (previously described in our laboratory: GM2AP, Transferrin, and t-Gelsolin) at the time of patient recruitment. At 24 months there will be a follow-up of the groups of patients without risk factors (groups 1 and 3), which will allow us to relate the levels of biomarkers of predisposition at the beginning of the study with renal function in the medium term. Renal function at the 24 month follow-up will be evaluated by biomarkers of early damage in addition to the usual clinical parameters (plasma creatinine, creatinine clearance, plasma urea, and proteinuria).

Objective 3. We will analyze the evolution of both early and predisposing damage markers 3, 6, and 12 months after the inclusion of patients in the study. This data will be used to analyze whether smoking cessation reduces subclinical renal damage and / or the risk of acute renal damage.

General variables

At the time of urine sample collection (see next section), the following data will be collected: (i) date of collection of the sample; (ii) general data (age, sex, drug use); anthropometric measurements (body weight, height, body mass index); analytical biochemistry (plasma creatinine and urea), allowing assessment of each patient's renal function. In the event that there is no clinical analysis carried out during the 6 months prior to sample collection, it will be carried out specifically for this purpose in the Biochemistry Department of the University Hospital of Salamanca; (iii) risk factors for kidney damage (hypertension, diabetes, cardiovascular disease, or chronic pain with frequent use of NSAIDs); (iv) Other information (in addition to the above, we will include the date of diagnosis, and dosage and start date of any prescribed medication); (v) tobacco use (the patient will complete a questionnaire adapted from the WHO Multinational Monitoring of trends and determinants in Cardiovascular disease (MONICA) study that will allow us to classify them as a smoker, non-smoker, or ex-smoker. We will also collect data on the number of cigarettes/cigars consumed per day, concentration of carbon monoxide in exhaled air [measured with a co-oximeter at the Health Center "La Alamedilla" as well as in the Tabaquic Detoxification Unit of the University Hospital of Salamanca], and blood concentration of cotinine, if available).

The information collected on risk factors and tobacco consumption will allow us to distribute patients into the appropriate study groups (see "Study design").

Collection and processing of urine samples

Objective 1. A single urine sample will be obtained at the time of inclusion in the study.

Objective 2. A urine sample will be obtained 24 months after the patient's inclusion in the study.

Objective 3. Urine samples will be obtained at the time of inclusion in the study (in the smoking cessation program), and at 3, 6, and 12 months after inclusion.

For peer review only

All samples will be collected in the relevant healthcare centre and transferred to the Samples Bank of the University Hospital of Salamanca, where they will be managed and conserved. On submission to the Biobank, samples will be centrifuged (2000 g, 4 ºC, for 8 minutes) to remove possible sediments. Subsequently, they will be frozen in several aliquots at -80 ºC until use.

Analysis of urine samples

The analyses necessary for the study will be carried out in the laboratories of the Theanostic group of Renal and Cardiovascular Diseases (TRECARD) of the Biosanitary Institute of Salamanca (IBSAL). These analyses will include the following:

Urinary creatinine: This will be used as a correction factor to adjust measured biomarkers for urinary flow. The ratio of Biomarker/urinary creatinine will be calculated. Creatinine levels will be determined using the colorimetric kit "Quantichrom™ Creatinine Assay Kit" (BioAssay Systems, Hayward, CA, USA), based on Jaffé's method.[16] It is estimated that urinary creatinine concentration will be inversely proportional to urinary flow.

Proteinuria: Urinary protein excretion will be evaluated by the Bradford colorimetric method.[17] It is estimated that proteinuria values in healthy patients will be 150 mg in 24 hours, or 0 - 8 mg/dL.[18]

Early markers of kidney damage (NAG, albuminuria, KIM-1, and NGAL): There are no reference values for humans, so the means of non-smoking patients without risk factors (group 1) will be compared with the other groups. All markers will be measured by commercial kits, following the instructions of the manufacturers. For NAG, the colorimetric kit "NAG assay kit" (Diazyme™, Poway, CA, USA) will be used. The other three markers will be measured using the enzyme-linked immunosorbent assay technique (ELISA). Specifically, we will use the "Human Albumin ELISA kit" (Bethyl Laboratories, Montgomery, USA) for albuminuria, the "Human KIM-1 ELISA kit" (Enzo Life Sciences, Lase, Suiza) for KIM-1, and the "Human NGAL ELISA kit 036CE™ (BioPorto Diagnostics, Hellerup, Dinamarca) for NGAL.

Predisposition markers (GM2AP, Transferrin, and t-Gelsolin): There are no reference values for humans, so the means of non-smoking patients without risk factors (group 1) will be compared with the other groups. These markers will be evaluated using the western blotting technique. Protein samples from 21 µL of urine will be separated by polyacrylamide gel electrophoresis (PAGE; Mini Protean II system, BioRad, Madrid, Spain). These proteins will subsequently be transferred to Immobilon P membranes (Millipore, Madrid, Spain), which will then be incubated with goat polyclonal antibodies against GM2AP (1:1000 dilution; own production), and then with rabbit polyclonal antibodies against GM2AP (1:10000 dilution, MBL

For peer review only

International, Woburn, MA, USA), Transferrin (1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and t-Gelsolin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by incubation with goat polyclonal antibodies against Transferrin and t-Gelsolin (Southern Biotech™, AL, USA). Following primary antibody incubations, membranes will be incubated with secondary antibodies coupled with horseradish peroxidase (HRP). Membranes will be subsequently incubated with the quimioluminiscent HRP-substrate (ECL; BioRad, Madrid, Spain), and exposed to photographic films (Kodak, Rochester, NY, USA). Bands will be quantified with Scion Image software (Scion Corporation, Frederick, MD, USA).

Tobacco use marker, urinary cotinine: This will be determined by a commercial kit, based on the colorimetric technique, following the manufacturer's instructions (Cotinine ELISA kit, Abnova Corporation, Taipei, Taiwan).

Statistical analysis

Results will be expressed as mean ± standard deviation for normally distributed quantitative variables, medians (and interquartile ranges) for skewed quantitative variables, and frequency distribution for qualitative variables. Statistical normality will be tested using the Kolmogorov-Smirnov test. Homoscedasticity will be tested using the Levene test. The Chi-square test and Fisher's exact test will be used to analyze the association between independent qualitative variables. Pearson Correlation or Rho de Spearman tests will be used to evaluate the relationships between quantitative variables. We will use comparison of means (ANOVA and Kruskal-Wallis) tests for independent data and repeated measures ANOVA and Wilcoxon tests for paired data.

Objective 1. The data obtained from all study patients will be analyzed and compared to assess renal function (through the different biomarkers), both qualitatively and quantitatively, based on the groups and risk factors described.

Objective 2. The data within the "smokers" group (group 3 of Table 1) will be compared with “no smokers” (group 1 of Table 1) through statistical techniques of repeated measures (ANOVA, Wilcoxon) to characterize the evolution of their renal function.

Objective 3. The data of patients who have given up smoking will be compared, with tools of repeated measures, to quantitatively determine the evolution of the biomarkers of renal function.

Multivariate analysis of multiple linear regression (GLM, logistic regression) will be performed to analyze the variables that most influence renal function, with the incorporation of variables such as gender, age, and weight. In this manner, we hope to obtain conclusions regarding the usefulness of the biomarkers in the prognosis of tobacco-associated kidney damage. The

For peer review only

hypotheses will be tested with alpha=0.05. The data will be analyzed using R and/or SPSS version 23.0 (IBM Corp., Armonk, NY, USA).

Dates of the study

The study began on March 4, 2019. The collection of samples will end in April 2022. The study will be completed in July 2022.

ETHICS AND DISSEMINATION

The study has been approved by the Clinical Research Ethics Committee of the Healthcare Area of Salamanca. Participants will be required to sign an informed consent form prior to inclusion in the study, in accordance with the Declaration of Helsinki,[19] and the WHO standards for observational studies. Our protocol will not in any way alter the standard procedure of the patients' healthcare. Participants will be informed of the objectives and potential benefits of the project. As the study includes the collection of biological samples, the study participants will be informed of this in detail. The confidentiality of the recruited participants will be ensured at all times in accordance with the provisions of current legislation on personal data protection (3/2018 of 5 December Protection of Personal Data Official Law), and the conditions contemplated by Act 14/2007 on biomedical research. Patients may withdraw freely from the study at any time.

The study results, given their applicability and implications for the general population, will be disseminated in research meetings and peer-reviewed scientific journals. On the other hand, this work seeks novel applications based on globally innovative concepts, with a large associated potential market. For these reasons, any new diagnostic systems developed from the study will be patented.

The study has been registered in ClinicalTrials.gov with identifier NCT03850756.

DISCUSSION

Smoking causes kidney damage that is not effectively detected by the diagnostic parameters usually used in the clinic, and can degenerate into long-term chronic kidney failure.[4-6] Our hypothesis is that certain early markers could detect such subclinical damage. This finding would be a preventive measure of great advantage to social and public health, in the face of two major health problems; smoking and chronic kidney disease.

For peer review only

The first strategy proposed in this project is to find early markers of kidney damage associated with tobacco consumption, in patients both with and without additional risk factors. The presence of these markers in apparently healthy smokers could raise awareness of the risk of progression to chronic kidney disease, and would help to generate protocols to modify avoidable risk factors. In addition, the detection of these early markers could be a useful factor to convince patients to stop smoking.

The second proposed strategy raises an innovative concept of intervention even earlier, before the damage occurs, which our research group has been a global pioneer in developing. Specifically, we have shown that some drugs and renal toxins in completely subtoxic doses can make experimental animals predisposed to, or more sensitive to, acute kidney injury,[20-23] with associated risk of chronic renal failure.[24] The relevance of this is that individuals apparently unaffected by a treatment, or exposure to toxins such as tobacco, could unknowingly be predisposed to developing acute kidney injury in certain circumstances (for example, other treatments, radiological contrasts, environmental toxicity) that do not harm non-predisposed individuals. Our group has identified and patented factors associated with this acquired hypersensitivity, and are clinically and technologically developing these as urinary markers.[20-23] The clinical application of these markers will allow us not only to detect predisposition, but to stratify patients in a preventive and personalized manner, according to their individual acquired risk resulting from apparently innocuous pharmacological treatments or chemical exposures.

In the case of smokers, this hypersensitivity becomes especially relevant, since it could have been acquired by the consumption of the multiple substances contained in tobacco. The possibility of identifying patients at risk could prevent possible acute kidney injury derived from, for example, treatments with potentially nephrotoxic drugs, administration of contrast media, or exposure to substances toxic to the kidney. The appearance of acute damage in this context could be of great importance, since it has been shown that acute kidney injury is a risk factor for the development of chronic kidney disease. Even after initial full recovery of renal function, some patients develop a progressive and persistent deterioration of renal function, and these patients are more likely to progress to end-stage renal disease.[25]

Finally, we also propose to study whether renal parameters and markers are restored with smoking cessation. This fact would consolidate the argument that tobacco is an avoidable risk in the progression and pathology of kidney disease, and also support the benefits of ceasing consumption.

In short, this project addresses two issues of high concern in the health field; smoking and chronic kidney disease. The concept is aimed at finding diagnostic tools for the early detection

For peer review only

of tobacco-associated chronic kidney damage, with a preventive method in terms of disease development, and a personalized method regarding each patient's individual hypersensitivity. The tools developed from this project could not only reduce the major economic and social costs associated with kidney disease, but could also act as deterrents to convince patients to stop smoking.

Study limitations

Although the study follows all the recommendations for observational studies considered in the STROBE statement (STrengthening the Reporting of OBservational studies in Epidemiology), there is a possibility that there are factors that have not been considered. The variables included are biomarkers of early kidney damage and predisposition to acute kidney injury induced by certain renal toxins. It is possible that there are other (unknown) markers with the potential to predict tobacco-associated kidney damage that we have not included in our project.

Ethics approval: The study has been approved by the Clinical Research Ethics Committee (CEIC) of the Health Area of Salamanca (PI05/01/2018, January 16, 2018).

Collaborators: Members of the BIOTAB (Project acronym; Biomarkers of kidney damage and tobacco) Group: Ana Isabel Morales Martín (AIM), Marta Prieto Vicente (MPr), Laura Vicente Vicente (LVV), Alfredo Ginés Casanova Paso (AC), María Teresa Hernández Sánchez (THS), Moisés Pescador Garriel, Ángela de Cabo Laso, Jesús González Sánchez, Natalia Sánchez Aguadero, Carmela Rodríguez Martín, Benigna Sánchez Salgado, Cristina Agudo Conde, Cristina Lugones Sánchez, Manuel Ángel Gómez Marcos (MGM), Luis García Ortiz (LGO), Miguel Ángel Hernández Mezquita, Miguel Barrueco Ferrero.

Author´s Contributions: AIM participated in the conception of the idea for the study. AIM, MPr and LVV participated in the design of the study, the development of the protocol and in the writing of the manuscript. AC, THS, MGM and LGO have reviewed the manuscript. The project will be conducted by the BIOTAB group.

Funding: This study was funded by the Spanish Ministry of Science Innovation and Universities (MICINN) and the Carlos III Health Institute/European Regional Development Fund (ERDF) (grant number: PI17/01979, RETICS RD16/0009/0025), and by Fundación Samuel Solórzano (University of Salamanca, Spain), grant number FS/23-2017.

Competing interests: None declared.

For peer review only

REFERENCES

1. World Health Organization. WHO report on the global tobacco epidemic 2015: raising taxes on tobacco. World Health Organization 2015.

2. Whelton PK, Perneger TV, He J, et al. The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. *J Hum Hypertens* 1996;10(10):683-689.

3. Pinto-Sietsma SJ, Mulder J, Janssen WM, et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. *Ann Intern Med* 2000;133(8):585-591.

4. Orth SR: Smoking--a renal risk factor. *Nephron* 2000;86(1):12-26.

5. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. *Nephrol Dial Transplant* 1994;9(8):1097-1102.

6. Hammer Y, Cohen E, Levi A, et al. The Relationship between Cigarette Smoking and Renal Function: A Large Cohort Study. *Isr Med Assoc J* 2016;18(9):553-556.

7. Stegmayr BG. A study of patients with diabetes mellitus (type 1) and end-stage renal failure: tobacco usage may increase risk of nephropathy and death. *J Intern Med* 1990;228(2):121-124.

8. Rocco MV, Soucie JM, Reboussin DM, et al. Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). *J Am Soc Nephrol* 1996;7(6):889-896.

9. Vargas M. Documento Marco sobre Enfermedad Renal Crónica (ERC) dentro de la estrategia de Abordaje a la cronicidad en el SNS. Subdirección General De Calidad y Cohesión. Ministerio de Sanidad. Gobierno de España. Consejerías de Sanidad de las CCAA.2015.

10. Blank MD, Cobb CO, Kilgalen B, et al. Acute effects of waterpipe tobacco smoking: a double-blind, placebo-control study. *Drug Alcohol Depend* 2011;116(1-3):102-109.

11. Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. *Clin Transl Sci* 2008;1(3):200-208.

12. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. *Annu Rev Pharmacol Toxicol* 2008;48:463-493.

13. Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. *Nat Biotechnol* 2010;28(5):436-440.

For peer review only

14. Zhou Y, Vaidya VS, Brown RP, et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. *Toxicol Sci* 2008;101(1):159-170.

15. World Health Organization. Research for International Tobacco Control. WHO report on the global tobacco epidemic, 2008: the MPOWER package. World Health Organization 2008

16. Jaffé M. (1886). Ueber den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins. *Zeitschrift für physiologische Chemie* 1886;10(5): 391-400.

17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical biochemistry* 1976;72, (1-2): 248-254.

18. Escalante-Gómez C, Zeledón-Sánchez F, Ulate-Montero G. Proteinuria, fisiología y fisiopatología aplicada. *Acta Médica Costarricense* 2007;49(2): 83-89.

19. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191–4.

20. Quiros Y, Ferreira L, Sancho-Martinez SM, et al: Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein. *Kidney Int* 2010;78(10):1006-1015.

21. Ferreira L, Quiros Y, Sancho-Martinez SM, et al: Urinary levels of regenerating islet-derived protein III beta and gelsolin differentiate gentamicin from cisplatin-induced acute kidney injury in rats. *Kidney Int* 2011;79(5):518-528.

22. Vicente-Vicente L, Ferreira L, Gonzalez-Buitrago JM, et al. Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats. *Toxicology* 2013;304:83-91.

23. Vicente-Vicente L, Sanchez-Juanes F, Garcia-Sanchez O, et al. Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase. *Toxicol Lett* 2015;234(2):99-109.

24. Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: From the laboratory to the clinic. *Nephrologie & therapeutique* 2016; 2:S41-S48.

25. Le Clef N, Verhulst A, D'Haese PC, et al. Unilateral Renal Ischemia-Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice. *PLoS One* 2016;11(3):e0152153.

For peer review only

FIGURE

Figure 1: Study design outline. Recruitment centers, patients distribution by groups, proposed objectives, and specific biomarkers for each objective. RF, Risk Factors; NAG, N-acetyl-beta-d-Glucosaminidase; KIM-1, Kidney Injury Molecule-1; NGAL, Neutrophil Gelatinase-Associated Lipocalin; GM2AP, Ganglioside GM2 Activator Protein; CAUSA, University Hospital of Salamanca

For peer review only


"La Alamedilla" Health Center
Basal(study inclusion)
Patients who attend primary care
Groups distribution
Group 1
n = 125
Group 2
n = 125
Group 3
n = 125
Group 4
n = 125
NO Smoker
NO RF
NO Smoker
YES RF
YES Smoker
NO RF
YES Smoker
YES RF
Follow-up: 24 months
Group 1
n = 100
Group 3
n = 100
OBJECTIVE 1:
Subclinical renal damage
Biomarkers (basal):
NAG
Albuminuria
KIM-1
NGAL
OBJECTIVE:2
Predisposition to kidney damage
Biomarkers (basal):
GM2AP
Transferrin
Gelsolin
Renal function evaluation
Biomarkers (follow-up)
NAG
Albuminuria
KIM-1
NGAL
Tabaquic Detoxification Unit CAUSA
Basal (study inclusion) n = 100
Patients who stop smoking
Follow-up: 3, 6, 12 months
OBJECTIVE:3
Renal function evaluation after smoking cessation
Biomarkers (basal and follow-up) :
NAG
Albuminuria
KIM-1
NGAL
GM2AP
Transferrin
Gelsolin

BMJ Open

AN OBSERVATIONAL PROSPECTIVE STUDY PROTOCOL TO DESIGN NEW DIAGNOSTIC SYSTEMS FOR THE EARLY DETECTION OF TOBACCO-ASSOCIATED CHRONIC RENAL DAMAGE IN PATIENTS OF A PRIMARY CARE CENTER OF SALAMANCA (SPAIN)

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2019-032918.R1
Article Type:	Protocol
Date Submitted by the Author:	04-Dec-2019
Complete List of Authors:	Prieto, Marta; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy Vicente-Vicente, Laura; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy Casanova, Alfredo G; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain Hernández-Sánchez, M Teresa; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain Gomez-Marcos, Manuel; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain Garcia-Ortiz, Luis; La Alamedilla health centre. University of Salamanca, Primary care research unit La Alamedilla Morales, Ana Isabel; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy;
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	General practice / Family practice
Keywords:	tobacco, kidney damage, biomarkers

SCHOLARONE™
Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2019-032918 on 8 March 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

For peer review only

AN OBSERVATIONAL PROSPECTIVE STUDY PROTOCOL TO DESIGN NEW DIAGNOSTIC SYSTEMS FOR THE EARLY DETECTION OF TOBACCO-ASSOCIATED CHRONIC RENAL DAMAGE IN PATIENTS OF A PRIMARY CARE CENTER OF SALAMANCA (SPAIN).

Marta Prieto[1,2,3], Laura Vicente-Vicente[1,2,3], Alfredo G Casanova[1,2,3], M Teresa Hernández-Sánchez[1,2,3], Manuel A Gomez-Marcos[2,4,5], Luis Garcia-Ortiz[2,4,6], Ana I Morales[1,2,3]

[1] Toxicology Unit, University of Salamanca, Salamanca, Spain

[2] Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

[3] Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), Salamanca, Spain.

[4] Primary Health Care Research Unit, La Alamedilla Health Center, Health Service of Castilla y León (SACyL),Salamanca, Spain

[5] Department of Medicine, University of Salamanca, Salamanca, Spain

[6] Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain

Corresponding Author:

Ana I Morales

Postal address: Postal Edificio Departamental, Lab 223, Campus Miguel de Unamuno, 37007 Salamanca, Spain

e-mail: amorales@usal.es

Telephone number: +34

Word count: 4033

For peer review only

ABSTRACT

Introduction: Tobacco causes kidney damage that can degenerate into chronic kidney disease. However, the diagnostic parameters used in the clinic are not effective at identifying smokers at risk.

Our first objective is to more effectively detect subclinical renal damage in smokers. In addition, we hypothesize that tobacco consumption can predispose smokers to renal damage on exposure to other potentially nephrotoxic events, (drugs, diagnostic procedures, etc.). We will test this hypothesis in our 2nd objective by investigating whether certain predisposition markers [GM2 Ganglioside Activator protein (GM2AP), Transferrin, and t-Gelsolin] are able to detect smokers who are predisposed to kidney damage. Finally (objective 3), we will study whether smoking cessation reduces subclinical and/or predisposition to renal damage.

Methods and analysis: For objective 1, a prospective cross-sectional study will be carried out with patients from a Primary Healthcare Centre. The influence of tobacco on renal damage, in patients both with and without additional risk factors, will be studied using a panel of early biomarkers [albuminuria, N-Acetyl-beta-D-glucosaminidase (NAG), Kidney Injury Molecule-1 (KIM-1), and Neutrophil gelatinase-associated lipocalin (NGAL)]. Objective 2 will be carried out through a prospective longitudinal study with the patients recruited in objective 1. We will study whether certain predisposition biomarkers (GM2AP, Transferrin, and t-Gelsolin) are able to detect smokers predisposed to renal damage. For objective 3, a prospective longitudinal study will be carried out with patients from a Smoking Cessation Unit. We will study the evolution of the markers described above following smoking cessation.

Ethics and dissemination: The study has been approved by the Clinical Research Ethics Committee of the Healthcare Area of Salamanca. All study participants will sign an informed consent form in compliance with the Declaration of Helsinki and the World Health Organization (WHO) standards for observational studies. Results will be presented at conferences and submitted to peer-reviewed journals.

Trial Registration number: NCT03850756

Keywords: Tobacco, kidney damage, biomarkers

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- In order to study the influence of tobacco on kidney damage, four groups of patients will be established: smokers and non-smokers, both with and without risk factors associated with kidney damage.
- We will study the relationship between smoking and urinary biomarkers of early kidney damage (albuminuria, NAG, KIM-1, and NGAL).
- We will analyze whether the predisposition/sensitization markers previously described in our laboratory are able to predict renal damage in smokers, in the medium term.
- We will test whether smoking cessation reduces subclinical renal damage and/or the risk of acute renal damage by analyzing the evolution of early damage and predisposition markers, respectively.
- The main limitation of this study is that it is possible there are other (unknown) markers with the potential to predict tobacco-associated kidney damage that we have not included in our project.

For peer review only

INTRODUCTION

Tobacco is one of the greatest threats to public health that the world has had to face. According to World Health Organization (WHO), smoking is the leading cause of preventable disease and death, and a major risk factor for the development of various respiratory and cardiovascular diseases, as well as cancer. It is the only product of legal consumption that harms all those exposed, being the cause of death of almost 6 million people a year, of which over 5 million are direct consumers, and over 600,000 are non-smokers exposed to second-hand smoke.[1]

Despite the fact that the first associations between smoking and kidney disease date back to the beginning of the last century, the evidence has so far been scarce, and inconclusive for those without kidney disease-associated risk factors. One of the first studies was "The Multiple Risk Factor Intervention Trial" (MRFIT) which observed that smoking was associated with terminal kidney disease in a dose-dependent manner.[2] Later, the study by Pinto-Sietsma et al. [3] "Prevention of Renal and Vascular Endstage Disease" (PREVEND), revealed a possible relationship between the number of cigarettes consumed per day and the prevalence of microalbuminuria, a marker of incipient renal damage. It was concluded that those who smoked more than 20 cigarettes per day had higher levels of microalbuminuria than non-smokers without additional risk factors, such as diabetes mellitus or high blood pressure. In addition, studies conducted with hypertensive patients have reported that the prevalence of microalbuminuria is almost doubled in smokers compared to non-smokers, and hypertensive patients who smoke more than 20 cigarettes per day have a prevalence of microalbuminuria 1.6 times higher.[4] In diabetes patients, it seems that the additional risk factor of smoking is related to an increase in microalbuminuria, which in turn produces an increased risk of developing proteinuria and accelerating the progression of kidney damage.[5] A large cohort study conducted in 2016 [6] found that smoking is associated with a high glomerular filtration rate, and a high prevalence of proteinuria, suggesting a mechanism of hyperfiltration that could progress to chronic kidney disease.

The increase in the worldwide prevalence of chronic kidney disease and the notable increase in the incidence of patients reaching the final stages [7] have alerted the health systems to invest more in the identification of potentially modifiable prevention factors.[8] Chronic kidney disease has a very high social and economic cost (almost 10% of the affected population and 3% of total health expenditure), which requires coordinated criteria among health professionals to ensure the highest quality in prevention, diagnosis, and treatment.[9] In addition, the identification of kidney disease as a cardiovascular risk factor, and the high morbidity and mortality associated with it, highlight the need for preventive strategies in potentially avoidable factors, such as tobacco use.[10]

For peer review only

It is recognized that the key to preventive success is very early diagnosis, allowing intervention while the renal functional reserve has not yet been exhausted and, therefore, the excretory function is not yet compromised.[11] In the clinic, one of the most common diagnostic tools for kidney damage is the detection of metabolic products (for example creatinine and urea), which accumulate in the blood once the renal excretory capacity begins to decrease. However, at the stage when serum urea and creatinine levels are detectably increased, more than 70% of renal function has already been lost. Thus, there is a current trend in diagnostics to identify sensitive, specific, and easily quantifiable markers that detect incipient pathophysiological events in the early stages, when the damage is less widespread.[12] These potential markers may, for example, be involved in the synthesis, activation, or inhibition of biochemical process mediators and cellular structural constituents related to processes such as apoptosis and tissue regeneration. Likewise, signs of destruction of tissues (extracellular matrix, and basal membranes) could be found in the urine, whether they are whole or degraded molecules, or remnants of organelles, cells, or tissues. The urinary detection of certain cellular enzymes associated with renal cell injury is currently the procedure for the early detection of the tubular subtype of kidney damage. In this sense, urinary detection of the enzyme N-Acetyl-beta-D-glucosaminidase (NAG) represents one of the finest techniques for the detection of tubular damage, although it is not established as a standard diagnostic technique.[13] Other markers, such as protein Kidney Injury Molecule-1 (KIM-1), or Neutrophil gelatinase-associated lipocalin (NGAL), are in an advanced stage of clinical development as early urinary markers of kidney damage.[14]. These markers of early renal damage (NAG; KIM-1 and NGAL), have also been evaluated as possible predictors in the development of chronic kidney disease. The results obtained with NAG and KIM-1 have been very promising, [15] whereas NGAL would also have this capacity according to some studies. [16]

Our hypothesis is that some of these early markers could detect the subclinical renal damage caused by tobacco.

Based on this hypothesis, we set the following objectives: (Objective 1) To detect subclinical renal damage in smokers through a panel of early markers (albuminuria, NAG, KIM-1, and NGAL); (Objective 2) To study whether certain predisposition markers previously identified in our group (GM2 Ganglioside Activator protein (GM2AP), Transferrin, and t-Gelsolin), [17–20] can detect those smokers who are predisposed to acute kidney injury; and (Objective 3) To study whether smoking cessation reduces subclinical renal damage and/or predisposition to acute kidney injury.

For peer review only

To this end, a consortium of researchers and clinicians has been created, consisting of: 1) experts in markers of kidney damage, 2) clinical specialists in lifestyles and cardiovascular risk, and 3) specialists in smoking cessation.

METHODS AND ANALYSIS

Study design

For the development of this project, 3 studies are proposed, each related to an objective (see Figure 1):

Objective 1. A prospective cross-sectional study is proposed to evaluate the usefulness of early markers in the diagnosis of renal damage associated with tobacco use. Four groups of patients will be established (Table 1) that will allow us to study the influence of tobacco on kidney damage, both in patients with and without risk factors.

Group	Smoker*	Risk factors**
1		
2		X
3	X	
4	X	X

Table 1. Groups of patients established in the study design. *Any person who habitually consumes tobacco at the time of sample collection or ceased smoking during the last year will be considered a smoker (see section "Collection and processing of urine samples").[21] **The following factors involved in the development of kidney damage will be considered risk factors: diabetes mellitus, hypertension, and/or frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs; more than three days a week during the three months prior to sampling). When a box is marked with "X" it is considered that in the group are included smokers (acording to the previous definition *) or patients with at least one of the risk factors mentioned (**) depending on the column considered.

Objective 2. A longitudinal prospective study is proposed to evaluate the usefulness of predisposition markers of predisposition to acute kidney injury in the context of the smoking patient. Patients from groups 1 and 3 (non-smokers and smokers without other risk factors that may influence predisposition, respectively) of objective 1 will be studied (see Table 1).

For peer review only

Objective 3. A prospective longitudinal study is proposed to evaluate whether the risk of renal damage decreases with the cessation of tobacco consumption. This will involve follow-up of patients from the Tabaquic Detoxification Unit of the University Hospital of Salamanca.

Sample size

The sample size has been estimated on the basis of detection of differences in the parameters analyzed between the four groups defined in objective 1. As information on the variability of microalbuminuria is available from previous studies of the population, this parameter has been used for the estimation. In a previous study from our group, [22] the mean and the standard deviation (SD) of the albumin/creatinine index was 14.8 ± 41.4 mg/g. therefore, a SD of 40 mg/g has been considered to estimate the sample size. Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 120 subjects in each group are required to detect a minimum difference of 18 mg/g of the albumin/creatinine index between two of the four groups, considering a common standard deviation of 40 mg/g. Each group has been increased by 5 subjects to account for possible losses due to technical issues, meaning that a total of 500 subjects will be recruited (125 per group). Using the same criterion, the number of patients needed for objective 3 has been estimated as 100.

Subjects of study

Objective 1. Patients of legal age from the "La Alamedilla" Health Center of Salamanca (Spain) will be included. A total of 500 patients will be recruited (125 per group) at the general practitioner consult until reaching the estimated sample size. During the recruitment process we will ensure that there are no significant differences in terms of gender and age between the groups. To that purpose, while the recruitment is done, statistical studies will be conducted to ensure that the groups are homogeneous in terms of gender and age. Thus, the subsequent recruitment can be directed to have homogeneous groups.

Objective 2. A follow-up of 200 patients recruited in the previous objective will be carried out, specifically 100 each from groups 1 and 3. This sample size has been estimated allowing for the possibility that some patients from objective 1 are unwilling or unable to participate in the study of objective 2.

Objective 3. We will recruit 100 patients who start treatment in the Tabaquic Detoxification Unit of the University Hospital of Salamanca.

Inclusion criteria

For peer review only

Patients of legal age who agree to participate in the study, sign the informed consent, meet the inclusion criteria previously specified for each group, and do not meet any of the exclusion criteria.

Exclusion criteria

Patients who are terminally ill, have previously been diagnosed with renal failure, do not wish to sign the informed consent, or have been treated with any of the following drugs during the week prior to, or at the time of, sample collection: aminoglycosides, cephalosporins, tetracyclines, amphotericin B, cisplatin, cyclosporine, foscarnet, acyclovir, cidofovir, radiological contrasts, or any other potentially nephrotoxic drugs.

Specific variables

Objective 1. We will analyze the presence of biomarkers of early kidney damage (albuminuria, NAG, KIM-1, and NGAL) at the time of patient recruitment. We will study the association of these markers with tobacco consumption with respect to the presence or absence of other risk factors for kidney damage.

Objective 2. We will analyze markers of predisposition to acute kidney injury (previously described in our laboratory: GM2AP, Transferrin, and t-Gelsolin) at the time of patient recruitment. At 24 months there will be a follow-up of the groups of patients without risk factors (groups 1 and 3), which will allow us to relate the levels of biomarkers of predisposition at the beginning of the study with renal function in the medium term. Renal function at the 24 month follow-up will be evaluated by biomarkers of early damage in addition to the usual clinical parameters (plasma creatinine, creatinine clearance, plasma urea, and proteinuria).

Objective 3. We will analyze the evolution of both early and predisposing damage markers 3, 6, and 12 months after the inclusion of patients in the study. This data will be used to analyze whether smoking cessation reduces subclinical renal damage and / or the risk of acute renal damage.

General variables

At the time of urine sample collection (see next section), the following data will be collected: (i) date of collection of the sample; (ii) general data (age, sex, drug use); anthropometric measurements (body weight, height, body mass index); biochemical parameters (plasma creatinine and urea), allowing assessment of each patient's renal function. In the event that there is no clinical analysis carried out during the 6 months prior to sample collection, it will be carried out specifically for this purpose in the Biochemistry Department of the University Hospital of Salamanca; (iii) risk factors for kidney damage (hypertension, diabetes, cardiovascular disease, or chronic pain with frequent use of NSAIDs); (iv) Other information

For peer review only

(in addition to the above, we will include the date of diagnosis, and dosage and start date of any prescribed medication); (v) tobacco use (the patient will complete a questionnaire adapted from the WHO Multinational Monitoring of trends and determinants in Cardiovascular disease (MONICA) study that will allow us to classify them as a smoker, non-smoker, or ex-smoker. We will also collect data on the number of cigarettes/cigars consumed per day, concentration of carbon monoxide in exhaled air [measured with a co-oximeter at the Health Center "La Alamedilla" as well as in the Tabaquic Detoxification Unit of the University Hospital of Salamanca], and blood concentration of cotinine, if available).

The information collected on risk factors and tobacco consumption will allow us to distribute patients into the appropriate study groups (see "Study design").

Collection and processing of urine samples

Objective 1. A single urine sample will be obtained at the time of inclusion in the study.
Objective 2. A urine sample will be obtained 24 months after the patient's inclusion in the study.
Objective 3. Urine samples will be obtained at the time of inclusion in the study (in the smoking cessation program), and at 3, 6, and 12 months after inclusion.

All samples will be collected in the relevant healthcare centre and transferred to the Samples Bank of the University Hospital of Salamanca, where they will be managed and conserved. On submission to the Biobank, samples will be centrifuged (2000 g, 4 ºC, for 8 minutes) to remove possible sediments. Subsequently, they will be frozen in several aliquots at -80 ºC until use.

Analysis of urine samples

The analyses necessary for the study will be carried out in the laboratories of the Theanostic group of Renal and Cardiovascular Diseases (TRECARD) of the Biosanitary Institute of Salamanca (IBSAL). These analyses will include the following:

Urinary creatinine: This will be used as a correction factor to adjust measured biomarkers for urinary flow. The ratio of Biomarker/urinary creatinine will be calculated. Creatinine levels will be determined using the colorimetric kit "Quantichrom™ Creatinine Assay Kit" (BioAssay Systems, Hayward, CA, USA), based on Jaffé's method.[23] It is estimated that urinary creatinine concentration will be inversely proportional to urinary flow.

Proteinuria: Urinary protein excretion will be evaluated by the Bradford colorimetric method.[24] It is estimated that proteinuria values in healthy patients should be 150 mg in 24 hours, or 0 - 8 mg/dL.[25]

Early markers of kidney damage (NAG, albuminuria, KIM-1, and NGAL): There are no reference values for humans, so the means of non-smoking patients without risk factors (group

For peer review only

1) will be compared with the other groups. All markers will be measured by commercial kits, following the instructions of the manufacturers. For NAG, the colorimetric kit "NAG assay kit" (Diazyme™, Poway, CA, USA) will be used. The other three markers will be measured using the enzyme-linked immunosorbent assay technique (ELISA). Specifically, we will use the "Human Albumin ELISA kit" (Bethyl Laboratories, Montgomery, USA) for albuminuria, the "Human KIM-1 ELISA kit" (Enzo Life Sciences, Lase, Suiza) for KIM-1, and the "Human NGAL ELISA kit 036CE™ (BioPorto Diagnostics, Hellerup, Dinamarca) for NGAL.

Predisposition markers (GM2AP, Transferrin, and t-Gelsolin): There are no reference values for humans, so the means of non-smoking patients without risk factors (group 1) will be compared with the other groups. These markers will be evaluated using the western blotting technique. Protein samples from 21 µL of urine will be separated by polyacrylamide gel electrophoresis (PAGE; Mini Protean II system, BioRad, Madrid, Spain). These proteins will subsequently be transferred to Immobilon P membranes (Millipore, Madrid, Spain), which will then be incubated with goat polyclonal antibodies against GM2AP (1:1000 dilution; own production), and then with rabbit polyclonal antibodies against GM2AP (1:10000 dilution, MBL International, Woburn, MA, USA), Transferrin (1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and t-Gelsolin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by incubation with goat polyclonal antibodies against Transferrin and t-Gelsolin (Southern Biotech™, AL, USA). Following primary antibody incubations, membranes will be incubated with secondary antibodies coupled with horseradish peroxidase (HRP). Membranes will be subsequently incubated with the quimioluminiscent HRP-substrate (ECL; BioRad, Madrid, Spain), and exposed to photographic films (Kodak, Rochester, NY, USA). Bands will be quantified with Scion Image software (Scion Corporation, Frederick, MD, USA).

Tobacco use marker, urinary cotinine: This will be determined by a commercial kit, based on the colorimetric technique, following the manufacturer's instructions (Cotinine ELISA kit, Abnova Corporation, Taipei, Taiwan).

Statistical analysis

Results will be expressed as mean ± standard deviation for normally distributed quantitative variables, medians (and interquartile ranges) for skewed quantitative variables, and frequency distribution for qualitative variables. Statistical normality will be tested using the Kolmogorov-Smirnov test. Homoscedasticity will be tested using the Levene test. The Chi-square test and Fisher's exact test will be used to analyze the association between independent qualitative variables. Pearson Correlation or rho de Spearman tests will be used to evaluate the relationships between quantitative variables. We will use comparison of means [Analysis of

For peer review only

variance (ANOVA) and Kruskal-Wallis] tests for independent data and repeated measures ANOVA and Wilcoxon tests for paired data.

Objective 1. The data obtained from all study patients will be analysed and compared to assess renal function (through the different biomarkers), both qualitatively and quantitatively, based on the groups and risk factors described.

Objective 2. The data within the "smokers" group (group 3 of Table 1) will be compared with "no smokers" (group 1 of Table 1) through statistical techniques of repeated measures (ANOVA, Wilcoxon) to characterize the evolution of their renal function.

Objective 3. The data of patients who have given up smoking will be compared, with tools of repeated measures, to quantitatively determine the evolution of the biomarkers of renal function.

Multivariate analysis of multiple linear regression (GLM, logistic regression) will be performed to analyze the variables that most influence renal function, with the incorporation of variables such as gender, age, and weight. In this manner, we hope to obtain conclusions regarding the usefulness of the biomarkers in the prognosis of tobacco-associated kidney damage. The hypotheses will be tested with alpha=0.05. The data will be analyzed using R and/or SPSS version 23.0 (IBM Corp., Armonk, NY, USA).

Patient and Public Involvement

At the end of the project, a report with the results of the study will be sent to the participating patients. Furthermore, the findings will be presented at a local congress, in which the public of the Salamanca Health Area will be invited to participate and will be disseminated through social networks and mass media.

Dates of the study

The study began on March 4, 2019. The collection of samples will end in April 2022. The study will be completed in July 2022.

ETHICS AND DISSEMINATION

The study has been approved by the Clinical Research Ethics Committee of the Healthcare Area of Salamanca. Participants will be required to sign an informed consent form prior to inclusion in the study, in accordance with the Declaration of Helsinki,[26] and the WHO standards for observational studies. Our protocol will not in any way alter the standard procedure of the patients' healthcare. Participants will be informed of the objectives and potential benefits of the project. As the study includes the collection of biological samples, the study participants will be

For peer review only

informed of this in detail. The confidentiality of the recruited participants will be ensured at all times in accordance with the provisions of current legislation on personal data protection (3/2018 of 5 December Protection of Personal Data Official Law), and the conditions contemplated by Act 14/2007 on biomedical research. Patients may withdraw freely from the study at any time.

The study results, given their applicability and implications for the general population, will be disseminated in research meetings and peer-reviewed scientific journals. On the other hand, this work seeks novel applications based on globally innovative concepts, with a large associated potential market. For these reasons, any new diagnostic systems developed from the study will be patented.

The study has been registered in ClinicalTrials.gov with identifier NCT03850756.

DISCUSSION

Smoking causes kidney damage that is not effectively detected by the diagnostic parameters usually used in the clinic, and can degenerate into long-term chronic kidney failure.[4–6] Our hypothesis is that certain early markers could detect such subclinical damage. This finding would be a preventive measure of great advantage to social and public health, in the face of two major health problems; smoking and chronic kidney disease.

The first strategy proposed in this project is to find early markers of kidney damage associated with tobacco consumption, in patients both with and without additional risk factors. The presence of these markers in apparently healthy smokers could raise awareness of the risk of progression to chronic kidney disease, and would help to generate protocols to modify avoidable risk factors. In addition, the detection of these early markers could be a useful factor to convince patients to stop smoking.

The second proposed strategy raises an innovative concept of intervention even earlier, before the damage occurs, which our research group has been a global pioneer in developing. Specifically, we have shown that some drugs and renal toxins in completely subtoxic doses can make experimental animals predisposed to, or more sensitive to, acute kidney injury,[17–20] with associated risk of chronic renal failure.[27] The relevance of this is that individuals apparently unaffected by a treatment, or exposure to toxins such as tobacco, could unknowingly be predisposed to developing acute kidney injury in certain circumstances (for example, other treatments, radiological contrasts, environmental toxicity) that do not harm non-predisposed individuals. Our group has identified and patented factors associated with this acquired hypersensitivity, and are clinically and technologically developing these as urinary markers.[17–

For peer review only

20] The clinical application of these markers will allow us not only to detect predisposition, but to stratify patients in a preventive and personalized manner, according to their individual acquired risk resulting from apparently innocuous pharmacological treatments or chemical exposures.

In the case of smokers, this hypersensitivity becomes especially relevant, since it could have been acquired by the consumption of the multiple substances contained in tobacco. The possibility of identifying patients at risk could prevent possible acute kidney injury derived from, for example, treatments with potentially nephrotoxic drugs, administration of contrast media, or exposure to substances toxic to the kidney. The appearance of acute damage in this context could be of great importance, since it has been shown that acute kidney injury is a risk factor for the development of chronic kidney disease. Even after initial full recovery of renal function, some patients develop a progressive and persistent deterioration of renal function, and these patients are more likely to progress to end-stage renal disease.[28]

Finally, we also propose to study whether renal parameters and markers are restored with smoking cessation. This fact would consolidate the argument that tobacco is an avoidable risk in the progression and pathology of kidney disease, and also support the benefits of ceasing consumption.

In short, this project addresses two issues of high concern in the health field; smoking and chronic kidney disease. The concept is aimed at finding diagnostic tools for the early detection of tobacco-associated chronic kidney damage, with a preventive method in terms of disease development, and a personalized method regarding each patient's individual hypersensitivity. The tools developed from this project could not only reduce the major economic and social costs associated with kidney disease, but could also act as deterrents to convince patients to stop smoking.

Study limitations

The variables included are biomarkers of early kidney damage and predisposition to acute kidney injury induced by certain renal toxins. It is possible that there are other (unknown) markers with the potential to predict tobacco-associated kidney damage that we have not included in our project.

Ethics approval: The study has been approved by the Clinical Research Ethics Committee (CEIC) of the Health Area of Salamanca (PI05/01/2018, January 16, 2018).

For peer review only

Collaborators: Members of the BIOTAB (Project acronym; Biomarkers of kidney damage and tobacco) Group: Ana Isabel Morales Martín (AIM), Marta Prieto Vicente (MPr), Laura Vicente Vicente (LVV), Alfredo Ginés Casanova Paso (AC), María Teresa Hernández Sánchez (THS), Moisés Pescador Garriel, Ángela de Cabo Laso, Jesús González Sánchez, Natalia Sánchez Aguadero, Carmela Rodríguez Martín, Benigna Sánchez Salgado, Cristina Agudo Conde, Cristina Lugones Sánchez, Manuel Ángel Gómez Marcos (MGM), Luis García Ortiz (LGO), Miguel Ángel Hernández Mezquita, Miguel Barrueco Ferrero.

Author´s Contributions: AIM participated in the conception of the idea for the study. AIM, MPr and LVV participated in the design of the study, the development of the protocol and in the writing of the manuscript. AC, THS, MGM and LGO have reviewed the manuscript. The project will be conducted by the BIOTAB group.

Funding: This study was funded by the Spanish Ministry of Science Innovation and Universities (MICINN) and the Carlos III Health Institute/European Regional Development Fund (ERDF) (grant number: PI17/01979, RETICS RD16/0009/0025), and by Fundación Samuel Solórzano (University of Salamanca, Spain), grant number FS/23-2017.

Acknowledgements: Authors would like to thank the patients participating in the project for their selfless collaboration.

Competing interests: None declared.

REFERENCES

1 World Health Organization. WHO report on the global tobacco epidemic 2015: raising taxes on tobacco. 2015.https://apps.who.int/iris/bitstream/handle/10665/178574/9789240694606_eng.pdf;jsessionid=6D7792BC1BD25368F5A92210218E7129?sequence=1 (accessed 4 May 2019).

2 Whelton PK, Perneger TV, He J, *et al.* The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. *J Hum Hypertens* 1996;**10**:683–9.

3 Pinto-Sietsma SJ, Mulder J, Janssen WM, *et al.* Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. *Ann Intern Med* 2000;**133**:585–91. doi:10.7326/0003-4819-133-8-200010170-00008

4 Orth SR. Smoking--a renal risk factor. *Nephron* 2000;**86**:12–26. doi:10.1159/000045708

5 Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. *Nephrol Dial Transplant* 1994;**9**:1097–102. doi:10.1093/ndt/9.8.1097

6 Hammer Y, Cohen E, Levi A, *et al.* The Relationship between Cigarette Smoking and Renal Function: A Large Cohort Study. *Isr Med Assoc J* 2016;**18**:553–6.

For peer review only

7 Stegmayr BG. A study of patients with diabetes mellitus (type 1) and end-stage renal failure: tobacco usage may increase risk of nephropathy and death. *J Intern Med* 1990;**228**:121–4. doi:10.1111/j.1365-2796.1990.tb00204.x

8 Rocco MV, Soucie JM, Reboussin DM, *et al.* Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). *JASN* 1996;**7**:889–96.

9 Vargas M. Documento Marco sobre Enfermedad Renal Crónica (ERC) dentro de la estrategia de Abordaje a la cronicidad en el SNS. Subdirección General De Calidad y Cohesión. Ministerio de Sanidad. Gobierno de España. Consejerías de Sanidad de las CCAA. 2015.https://www.mscbs.gob.es/organizacion/sns/planCalidadSNS/pdf/Enfermedad_Renal_Cronica_2015.pdf (accessed 20 May 2019).

10 Blank MD, Cobb CO, Kilgalen B, *et al.* Acute effects of waterpipe tobacco smoking: a double-blind, placebo-control study. *Drug Alcohol Depend* 2011;**116**:102–9. doi:10.1016/j.drugalcdep.2010.11.026

11 Vaidya VS, Waikar SS, Ferguson MA, *et al.* Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. *Clin Transl Sci* 2008;**1**:200–8. doi:10.1111/j.1752-8062.2008.00053.x

12 Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of Acute Kidney Injury. *Annu Rev Pharmacol Toxicol* 2008;**48**:463–93. doi:10.1146/annurev.pharmtox.48.113006.094615

13 Bonventre JV, Vaidya VS, Schmouder R, *et al.* Next-generation biomarkers for detecting kidney toxicity. *Nat Biotechnol* 2010;**28**:436–40. doi:10.1038/nbt0510-436

14 Zhou Y, Vaidya VS, Brown RP, *et al.* Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. *Toxicol Sci* 2008;**101**:159–70. doi:10.1093/toxsci/kfm260

15 Jungbauer CG, Uecer E, Stadler S, *et al.* N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure. *Nephrology (Carlton)* 2016;**21**:490–8. doi:10.1111/nep.12632

16 Devarajan P. The Use of Targeted Biomarkers for Chronic Kidney Disease. *Adv Chronic Kidney Dis* 2010;**17**:469–79. doi:10.1053/j.ackd.2010.09.002

17 Vicente-Vicente L, Ferreira L, González-Buitrago JM, *et al.* Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats. *Toxicology* 2013;**304**:83–91. doi:10.1016/j.tox.2012.12.006

18 Vicente-Vicente L, Sánchez-Juanes F, García-Sánchez O, *et al.* Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase. *Toxicol Lett* 2015;**234**:99–109. doi:10.1016/j.toxlet.2014.11.033

19 Ferreira L, Quiros Y, Sancho-Martínez SM, *et al.* Urinary levels of regenerating islet-derived protein III β and gelsolin differentiate gentamicin from cisplatin-induced acute kidney injury in rats. *Kidney International* 2011;**79**:518–28. doi:10.1038/ki.2010.439

20 Quiros Y, Ferreira L, Sancho-Martínez SM, *et al.* Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein. *Kidney Int* 2010;**78**:1006–15. doi:10.1038/ki.2010.267

For peer review only

21 World Health Organization. Research for International Tobacco Control. WHO report on the global tobacco epidemic. The MPOWER package. 2008.https://apps.who.int/iris/bitstream/handle/10665/43818/9789241596282_eng.pdf?sequence=1 (accessed 31 May 2019).

22 Gomez-Marcos MA, Martinez-Salgado C, Gonzalez-Sarmiento R, *et al.* Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study. *BMJ Open* 2016;**6**:e011031. doi:10.1136/bmjopen-2016-011031

23 Jaffe M. Ueber den Niederschlag welchen Pikrinsäure in normalen Harn erzeugt und über eine neue reaction des Kreatinins. *Z Physiol Chem* 1886;**10**:391–400.

24 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry* 1976;**72**:248–54. doi:10.1016/0003-2697(76)90527-3

25 Escalante-Gómez C, Zeledón-Sánchez F, Ulate-Montero G. Proteinuria,fisiología y fisiopatología aplicada. *Acta Médica Costarricense* 2007;**49**:83–9.

26 World Medical Association. WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (accessed 15 Apr 2019).

27 Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: From the laboratory to the clinic. *Nephrol Ther* 2016;**12 Suppl 1**:S41-48. doi:10.1016/j.nephro.2016.02.005

28 Le Clef N, Verhulst A, D'Haese PC, *et al.* Unilateral Renal Ischemia-Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice. *PLoS ONE* 2016;**11**:e0152153. doi:10.1371/journal.pone.0152153

FIGURE

Figure 1: Study design outline. Recruitment centers, patients' distribution by groups, proposed objectives, and specific biomarkers for each objective. RF, Risk Factors; NAG, N-acetyl-beta-D-Glucosaminidase; KIM-1, Kidney Injury Molecule-1; NGAL, Neutrophil Gelatinase-Associated Lipocalin; GM2AP, Ganglioside GM2 Activator Protein; CAUSA, University Hospital of Salamanca

For peer review only



90x92mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2019-032918 on 8 March 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

BMJ Open

AN OBSERVATIONAL PROSPECTIVE STUDY PROTOCOL TO DESIGN NEW DIAGNOSTIC SYSTEMS FOR THE EARLY DETECTION OF TOBACCO-ASSOCIATED CHRONIC RENAL DAMAGE IN PATIENTS OF A PRIMARY CARE CENTER OF SALAMANCA (SPAIN)

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2019-032918.R2
Article Type:	Protocol
Date Submitted by the Author:	28-Jan-2020
Complete List of Authors:	Prieto, Marta; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy Vicente-Vicente, Laura; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy Casanova, Alfredo G; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain Hernández-Sánchez, M Teresa; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain Gomez-Marcos, Manuel; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain Garcia-Ortiz, Luis; La Alamedilla health centre. University of Salamanca, Primary care research unit La Alamedilla Morales, Ana Isabel; University of Salamanca Faculty of Pharmacy, Physiology and Pharmalogy;
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	General practice / Family practice
Keywords:	tobacco, kidney damage, biomarkers

SCHOLARONE™
Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2019-032918 on 8 March 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

For peer review only

AN OBSERVATIONAL PROSPECTIVE STUDY PROTOCOL TO DESIGN NEW DIAGNOSTIC SYSTEMS FOR THE EARLY DETECTION OF TOBACCO-ASSOCIATED CHRONIC RENAL DAMAGE IN PATIENTS OF A PRIMARY CARE CENTER OF SALAMANCA (SPAIN).

Marta Prieto[1,2,3], Laura Vicente-Vicente[1,2,3], Alfredo G Casanova[1,2,3], M Teresa Hernández-Sánchez[1,2,3], Manuel A Gomez-Marcos[2,4,5], Luis Garcia-Ortiz[2,4,6], Ana I Morales[1,2,3]

[1] Toxicology Unit, University of Salamanca, Salamanca, Spain

[2] Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.

[3] Group of Translational Research on Renal and Cardiovascular Diseases (TRECARD), Salamanca, Spain.

[4] Primary Health Care Research Unit, La Alamedilla Health Center, Health Service of Castilla y León (SACyL),Salamanca, Spain

[5] Department of Medicine, University of Salamanca, Salamanca, Spain

[6] Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain

Corresponding Author:

Ana I Morales

Postal address: Postal Edificio Departamental, Lab 223, Campus Miguel de Unamuno, 37007 Salamanca, Spain

e-mail: amorales@usal.es

Telephone number: +34

Word count: 4033

For peer review only

ABSTRACT

Introduction: Tobacco causes kidney damage that can degenerate into chronic kidney disease. However, the diagnostic parameters used in the clinic are not effective at identifying smokers at risk.

Our first objective is to more effectively detect subclinical renal damage in smokers. In addition, we hypothesize that tobacco consumption can predispose smokers to renal damage on exposure to other potentially nephrotoxic events, (drugs, diagnostic procedures, etc.). We will test this hypothesis in our 2nd objective by investigating whether certain predisposition markers [GM2 Ganglioside Activator protein (GM2AP), Transferrin, and t-Gelsolin] are able to detect smokers who are predisposed to kidney damage. Finally (objective 3), we will study whether smoking cessation reduces subclinical and/or predisposition to renal damage.

Methods and analysis: For objective 1, a prospective cross-sectional study will be carried out with patients from a Primary Healthcare Centre. The influence of tobacco on renal damage, in patients both with and without additional risk factors, will be studied using a panel of early biomarkers [albuminuria, N-Acetyl-beta-D-glucosaminidase (NAG), Kidney Injury Molecule-1 (KIM-1), and Neutrophil gelatinase-associated lipocalin (NGAL)]. Objective 2 will be carried out through a prospective longitudinal study with the patients recruited in objective 1. We will study whether certain predisposition biomarkers (GM2AP, Transferrin, and t-Gelsolin) are able to detect smokers predisposed to renal damage. For objective 3, a prospective longitudinal study will be carried out with patients from a Smoking Cessation Unit. We will study the evolution of the markers described above following smoking cessation.

Ethics and dissemination: The study has been approved by the Clinical Research Ethics Committee of the Healthcare Area of Salamanca. All study participants will sign an informed consent form in compliance with the Declaration of Helsinki and the World Health Organization (WHO) standards for observational studies. Results will be presented at conferences and submitted to peer-reviewed journals.

Trial Registration number: NCT03850756

Keywords: Tobacco, kidney damage, biomarkers

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- In this work, the effect of tobacco on the kidney will be evaluated taking into account the influence of several risk factors (hypertension, diabetes ...), so patients will be grouped according to whether or not have them.

- A battery of new markers of kidney damage (early and predisposition) will be analyzed to more accurately establish the relationship tobacco-kidney damage or tobacco-susceptibility to kidney damage

- The results obtained in this work may help clinicians in making decisions about the prescription of potentially nephrotoxic drugs in smoking patients, depending on the values of their renal damage markers

- For the first time it will be assessed if smoking cessation reduces subclinical renal damage and/or the risk of acute renal damage by analyzing early and predisposition biomarkers.

- The main limitation of this study is that it is possible that there are other (unknown) markers with the potential to predict tobacco-associated kidney damage that we have not included in our project.

For peer review only

INTRODUCTION

Tobacco is one of the greatest threats to public health that the world has had to face. According to World Health Organization (WHO), smoking is the leading cause of preventable disease and death, and a major risk factor for the development of various respiratory and cardiovascular diseases, as well as cancer. It is the only product of legal consumption that harms all those exposed, being the cause of death of almost 6 million people a year, of which over 5 million are direct consumers, and over 600,000 are non-smokers exposed to second-hand smoke.[1]

Despite the fact that the first associations between smoking and kidney disease date back to the beginning of the last century, the evidence has so far been scarce, and inconclusive for those without kidney disease-associated risk factors. One of the first studies was "The Multiple Risk Factor Intervention Trial" (MRFIT) which observed that smoking was associated with terminal kidney disease in a dose-dependent manner.[2] Later, the study by Pinto-Sietsma et al. [3] "Prevention of Renal and Vascular Endstage Disease" (PREVEND), revealed a possible relationship between the number of cigarettes consumed per day and the prevalence of microalbuminuria, a marker of incipient renal damage. It was concluded that those who smoked more than 20 cigarettes per day had higher levels of microalbuminuria than non-smokers without additional risk factors, such as diabetes mellitus or high blood pressure. In addition, studies conducted with hypertensive patients have reported that the prevalence of microalbuminuria is almost doubled in smokers compared to non-smokers, and hypertensive patients who smoke more than 20 cigarettes per day have a prevalence of microalbuminuria 1.6 times higher.[4] In diabetes patients, it seems that the additional risk factor of smoking is related to an increase in microalbuminuria, which in turn produces an increased risk of developing proteinuria and accelerating the progression of kidney damage.[5] A large cohort study conducted in 2016 [6] found that smoking is associated with a high glomerular filtration rate, and a high prevalence of proteinuria, suggesting a mechanism of hyperfiltration that could progress to chronic kidney disease.

The increase in the worldwide prevalence of chronic kidney disease and the notable increase in the incidence of patients reaching the final stages [7] have alerted the health systems to invest more in the identification of potentially modifiable prevention factors.[8] Chronic kidney disease has a very high social and economic cost (almost 10% of the affected population and 3% of total health expenditure), which requires coordinated criteria among health professionals to ensure the highest quality in prevention, diagnosis, and treatment.[9] In addition, the identification of kidney disease as a cardiovascular risk factor, and the high morbidity and mortality associated with it, highlight the need for preventive strategies in potentially avoidable factors, such as tobacco use.[10]

For peer review only

It is recognized that the key to preventive success is very early diagnosis, allowing intervention while the renal functional reserve has not yet been exhausted and, therefore, the excretory function is not yet compromised.[11] In the clinic, one of the most common diagnostic tools for kidney damage is the detection of metabolic products (for example creatinine and urea), which accumulate in the blood once the renal excretory capacity begins to decrease. However, at the stage when serum urea and creatinine levels are detectably increased, more than 70% of renal function has already been lost. Thus, there is a current trend in diagnostics to identify sensitive, specific, and easily quantifiable markers that detect incipient pathophysiological events in the early stages, when the damage is less widespread.[12] These potential markers may, for example, be involved in the synthesis, activation, or inhibition of biochemical process mediators and cellular structural constituents related to processes such as apoptosis and tissue regeneration. Likewise, signs of destruction of tissues (extracellular matrix, and basal membranes) could be found in the urine, whether they are whole or degraded molecules, or remnants of organelles, cells, or tissues. The urinary detection of certain cellular enzymes associated with renal cell injury is currently the procedure for the early detection of the tubular subtype of kidney damage. In this sense, urinary detection of the enzyme N-Acetyl-beta-D-glucosaminidase (NAG) represents one of the finest techniques for the detection of tubular damage, although it is not established as a standard diagnostic technique.[13] Other markers, such as protein Kidney Injury Molecule-1 (KIM-1), or Neutrophil gelatinase-associated lipocalin (NGAL), are in an advanced stage of clinical development as early urinary markers of kidney damage.[14]. These markers of early renal damage (NAG; KIM-1 and NGAL), have also been evaluated as possible predictors in the development of chronic kidney disease. The results obtained with NAG and KIM-1 have been very promising, [15] whereas NGAL would also have this capacity according to some studies. [16]

Our hypothesis is that some of these early markers could detect the subclinical renal damage caused by tobacco.

Based on this hypothesis, we set the following objectives: (Objective 1) To detect subclinical renal damage in smokers through a panel of early markers (albuminuria, NAG, KIM-1, and NGAL); (Objective 2) To study whether certain predisposition markers previously identified in our group (GM2 Ganglioside Activator protein (GM2AP), Transferrin, and t-Gelsolin), [17–20] can detect those smokers who are predisposed to acute kidney injury; and (Objective 3) To study whether smoking cessation reduces subclinical renal damage and/or predisposition to acute kidney injury.

For peer review only

To this end, a consortium of researchers and clinicians has been created, consisting of: 1) experts in markers of kidney damage, 2) clinical specialists in lifestyles and cardiovascular risk, and 3) specialists in smoking cessation.

METHODS AND ANALYSIS

Study design

For the development of this project, 3 studies are proposed, each related to an objective (see Figure 1):

Objective 1. A prospective cross-sectional study is proposed to evaluate the usefulness of early markers in the diagnosis of renal damage associated with tobacco use. Four groups of patients will be established (Table 1) that will allow us to study the influence of tobacco on kidney damage, both in patients with and without risk factors.

Group	Smoker*	Risk factors**
1		
2		X
3	X	
4	X	X

Table 1. Groups of patients established in the study design. *Any person who habitually consumes tobacco at the time of sample collection or ceased smoking during the last year will be considered a smoker (see section "Collection and processing of urine samples").[21] **The following factors involved in the development of kidney damage will be considered risk factors: diabetes mellitus, hypertension, and/or frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs; more than three days a week during the three months prior to sampling). When a box is marked with "X" it is considered that in the group are included smokers (according to the previous definition *) or patients with at least one of the risk factors mentioned (**) depending on the column considered.

Objective 2. A longitudinal prospective study is proposed to evaluate the usefulness of predisposition markers of predisposition to acute kidney injury in the context of the smoking patient. Patients from groups 1 and 3 (non-smokers and smokers without other risk factors that may influence predisposition, respectively) of objective 1 will be studied (see Table 1).

For peer review only

Objective 3. A prospective longitudinal study is proposed to evaluate whether the risk of renal damage decreases with the cessation of tobacco consumption. This will involve follow-up of patients from the Tabaquic Detoxification Unit of the University Hospital of Salamanca.

Sample size

The sample size has been estimated on the basis of detection of differences in the parameters analyzed between the four groups defined in objective 1. As information on the variability of microalbuminuria is available from previous studies of the population, this parameter has been used for the estimation. In a previous study from our group, [22] the mean and the standard deviation (SD) of the albumin/creatinine index was 14.8 ± 41.4 mg/g. therefore, a SD of 40 mg/g has been considered to estimate the sample size. Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 120 subjects in each group are required to detect a minimum difference of 18 mg/g of the albumin/creatinine index between two of the four groups, considering a common standard deviation of 40 mg/g. Each group has been increased by 5 subjects to account for possible losses due to technical issues, meaning that a total of 500 subjects will be recruited (125 per group). Using the same criterion, the number of patients needed for objective 3 has been estimated as 100.

Subjects of study

Objective 1. Patients of legal age from the "La Alamedilla" Health Center of Salamanca (Spain) will be included. A total of 500 patients will be recruited (125 per group) at the general practitioner consult until reaching the estimated sample size. During the recruitment process we will ensure that there are no significant differences in terms of gender and age between the groups. To that purpose, while the recruitment is done, statistical studies will be conducted to ensure that the groups are homogeneous in terms of gender and age. Thus, the subsequent recruitment can be directed to have homogeneous groups.

Objective 2. A follow-up of 200 patients recruited in the previous objective will be carried out, specifically 100 each from groups 1 and 3. This sample size has been estimated allowing for the possibility that some patients from objective 1 are unwilling or unable to participate in the study of objective 2.

Objective 3. We will recruit 100 patients who start treatment in the Tabaquic Detoxification Unit of the University Hospital of Salamanca.

Inclusion criteria

For peer review only

Patients of legal age who agree to participate in the study, sign the informed consent, meet the inclusion criteria previously specified for each group, and do not meet any of the exclusion criteria.

Exclusion criteria

Patients who are terminally ill, have previously been diagnosed with renal failure, do not wish to sign the informed consent, or have been treated with any of the following drugs during the week prior to, or at the time of, sample collection: aminoglycosides, cephalosporins, tetracyclines, amphotericin B, cisplatin, cyclosporine, foscarnet, acyclovir, cidofovir, radiological contrasts, or any other potentially nephrotoxic drugs.

Specific variables

Objective 1. We will analyze the presence of biomarkers of early kidney damage (albuminuria, NAG, KIM-1, and NGAL) at the time of patient recruitment. We will study the association of these markers with tobacco consumption with respect to the presence or absence of other risk factors for kidney damage.

Objective 2. We will analyze markers of predisposition to acute kidney injury (previously described in our laboratory: GM2AP, Transferrin, and t-Gelsolin) at the time of patient recruitment. At 24 months there will be a follow-up of the groups of patients without risk factors (groups 1 and 3), which will allow us to relate the levels of biomarkers of predisposition at the beginning of the study with renal function in the medium term. Renal function at the 24 month follow-up will be evaluated by biomarkers of early damage in addition to the usual clinical parameters (plasma creatinine, creatinine clearance, plasma urea, and proteinuria).

Objective 3. We will analyze the evolution of both early and predisposing damage markers 3, 6, and 12 months after the inclusion of patients in the study. This data will be used to analyze whether smoking cessation reduces subclinical renal damage and / or the risk of acute renal damage.

General variables

At the time of urine sample collection (see next section), the following data will be collected: (i) date of collection of the sample; (ii) general data (age, sex, drug use); anthropometric measurements (body weight, height, body mass index); biochemical parameters (plasma creatinine and urea), allowing assessment of each patient's renal function. In the event that there is no clinical analysis carried out during the 6 months prior to sample collection, it will be carried out specifically for this purpose in the Biochemistry Department of the University Hospital of Salamanca; (iii) risk factors for kidney damage (hypertension, diabetes, cardiovascular disease, or chronic pain with frequent use of NSAIDs); (iv) Other information (in addition to the above,

For peer review only

we will include the date of diagnosis, and dosage and start date of any prescribed medication); (v) tobacco use (the patient will complete a questionnaire adapted from the WHO Multinational Monitoring of trends and determinants in Cardiovascular disease (MONICA) study that will allow us to classify them as a smoker, non-smoker, or ex-smoker. We will also collect data on the number of cigarettes/cigars consumed per day, concentration of carbon monoxide in exhaled air [measured with a co-oximeter at the Health Center "La Alamedilla" as well as in the Tabaquic Detoxification Unit of the University Hospital of Salamanca], and blood concentration of cotinine, if available).

The information collected on risk factors and tobacco consumption will allow us to distribute patients into the appropriate study groups (see "Study design").

Collection and processing of urine samples

Objective 1. A single urine sample will be obtained at the time of inclusion in the study.
Objective 2. A urine sample will be obtained 24 months after the patient's inclusion in the study.
Objective 3. Urine samples will be obtained at the time of inclusion in the study (in the smoking cessation program), and at 3, 6, and 12 months after inclusion.

All samples will be collected in the relevant healthcare centre and transferred to the Samples Bank of the University Hospital of Salamanca, where they will be managed and conserved. On submission to the Biobank, samples will be centrifuged (2000 g, 4 ºC, for 8 minutes) to remove possible sediments. Subsequently, they will be frozen in several aliquots at -80 ºC until use.

Analysis of urine samples

The analyses necessary for the study will be carried out in the laboratories of the Theranostic group of Renal and Cardiovascular Diseases (TRECARD) of the Biosanitary Institute of Salamanca (IBSAL). These analyses will include the following:

Urinary creatinine: This will be used as a correction factor to adjust measured biomarkers for urinary flow. The ratio of Biomarker/urinary creatinine will be calculated. Creatinine levels will be determined using the colorimetric kit “Quantichrom™ Creatinine Assay Kit” (BioAssay Systems, Hayward, CA, USA), based on Jaffé's method.[23] It is estimated that urinary creatinine concentration will be inversely proportional to urinary flow.

Proteinuria: Urinary protein excretion will be evaluated by the Bradford colorimetric method.[24] It is estimated that proteinuria values in healthy patients should be 150 mg in 24 hours, or 0 - 8 mg/dL.[25]

Early markers of kidney damage (NAG, albuminuria, KIM-1, and NGAL): There are no reference values for humans, so the means of non-smoking patients without risk factors (group 1) will be

For peer review only

compared with the other groups. All markers will be measured by commercial kits, following the instructions of the manufacturers. For NAG, the colorimetric kit "NAG assay kit" (Diazyme™, Poway, CA, USA) will be used. The other three markers will be measured using the enzyme-linked immunosorbent assay technique (ELISA). Specifically, we will use the "Human Albumin ELISA kit" (Bethyl Laboratories, Montgomery, USA) for albuminuria, the "Human KIM-1 ELISA kit" (Enzo Life Sciences, Lase, Switzerland) for KIM-1, and the "Human NGAL ELISA kit 036CE™ (BioPorto Diagnostics, Hellerup, Denmark) for NGAL.

Predisposition markers (GM2AP, Transferrin, and t-Gelsolin): There are no reference values for humans, so the means of non-smoking patients without risk factors (group 1) will be compared with the other groups. These markers will be evaluated using the western blotting technique. Protein samples from 21 µL of urine will be separated by polyacrylamide gel electrophoresis (PAGE; Mini Protean II system, BioRad, Madrid, Spain). These proteins will subsequently be transferred to Immobilon P membranes (Millipore, Madrid, Spain), which will then be incubated with goat polyclonal antibodies against GM2AP (1:1000 dilution; own production), and then with rabbit polyclonal antibodies against GM2AP (1:10000 dilution, MBL International, Woburn, MA, USA), Transferrin (1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), and t-Gelsolin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by incubation with goat polyclonal antibodies against Transferrin and t-Gelsolin (Southern Biotech™, AL, USA). Following primary antibody incubations, membranes will be incubated with secondary antibodies coupled with horseradish peroxidase (HRP). Membranes will be subsequently incubated with the chemiluminescent HRP-substrate (ECL; BioRad, Madrid, Spain), and exposed to photographic films (Kodak, Rochester, NY, USA). Bands will be quantified with Scion Image software (Scion Corporation, Frederick, MD, USA).

Tobacco use marker, urinary cotinine: This will be determined by a commercial kit, based on the colorimetric technique, following the manufacturer's instructions (Cotinine ELISA kit, Abnova Corporation, Taipei, Taiwan).

Statistical analysis

Results will be expressed as mean ± standard deviation for normally distributed quantitative variables, medians (and interquartile ranges) for skewed quantitative variables, and frequency distribution for qualitative variables. Statistical normality will be tested using the Kolmogorov-Smirnov test. Homoscedasticity will be tested using the Levene test. The Chi-square test and Fisher's exact test will be used to analyze the association between independent qualitative variables. Pearson Correlation or rho de Spearman tests will be used to evaluate the relationships between quantitative variables. We will use comparison of means [Analysis of variance

For peer review only

(ANOVA) and Kruskal-Wallis] tests for independent data and repeated measures ANOVA and Wilcoxon tests for paired data.

Objective 1. The data obtained from all study patients will be analysed and compared to assess renal function (through the different biomarkers), both qualitatively and quantitatively, based on the groups and risk factors described.

Objective 2. The data within the "smokers" group (group 3 of Table 1) will be compared with “no smokers” (group 1 of Table 1) through statistical techniques of repeated measures (ANOVA, Wilcoxon) to characterize the evolution of their renal function.

Objective 3. The data of patients who have given up smoking will be compared, with tools of repeated measures, to quantitatively determine the evolution of the biomarkers of renal function.

Multivariate analysis of multiple linear regression (GLM, logistic regression) will be performed to analyze the variables that most influence renal function, with the incorporation of variables such as gender, age, and weight. In this manner, we hope to obtain conclusions regarding the usefulness of the biomarkers in the prognosis of tobacco-associated kidney damage. The hypotheses will be tested with alpha=0.05. The data will be analyzed using R and/or SPSS version 23.0 (IBM Corp., Armonk, NY, USA).

Patient and Public Involvement

At the end of the project, a report with the results of the study will be sent to the participating patients. Furthermore, the findings will be presented at a local congress, in which the public of the Salamanca Health Area will be invited to participate and will be disseminated through social networks and mass media.

Dates of the study

The study began on March 4, 2019. The collection of samples will end in April 2022. The study will be completed in July 2022.

ETHICS AND DISSEMINATION

The study has been approved by the Clinical Research Ethics Committee of the Healthcare Area of Salamanca. Participants will be required to sign an informed consent form prior to inclusion in the study, in accordance with the Declaration of Helsinki,[26] and the WHO standards for observational studies. Our protocol will not in any way alter the standard procedure of the patients’ healthcare. Participants will be informed of the objectives and potential benefits of the project. As the study includes the collection of biological samples, the study participants will be

For peer review only

informed of this in detail. The confidentiality of the recruited participants will be ensured at all times in accordance with the provisions of current legislation on personal data protection (3/2018 of 5 December Protection of Personal Data Official Law), and the conditions contemplated by Act 14/2007 on biomedical research. Patients may withdraw freely from the study at any time.

The study results, given their applicability and implications for the general population, will be disseminated in research meetings and peer-reviewed scientific journals. On the other hand, this work seeks novel applications based on globally innovative concepts, with a large associated potential market. For these reasons, any new diagnostic systems developed from the study will be patented.

The study has been registered in ClinicalTrials.gov with identifier NCT03850756.

DISCUSSION

Smoking causes kidney damage that is not effectively detected by the diagnostic parameters usually used in the clinic, and can degenerate into long-term chronic kidney failure.[4–6] Our hypothesis is that certain early markers could detect such subclinical damage. This finding would be a preventive measure of great advantage to social and public health, in the face of two major health problems; smoking and chronic kidney disease.

The first strategy proposed in this project is to find early markers of kidney damage associated with tobacco consumption, in patients both with and without additional risk factors. The presence of these markers in apparently healthy smokers could raise awareness of the risk of progression to chronic kidney disease, and would help to generate protocols to modify avoidable risk factors. In addition, the detection of these early markers could be a useful factor to convince patients to stop smoking.

The second proposed strategy raises an innovative concept of intervention even earlier, before the damage occurs, which our research group has been a global pioneer in developing. Specifically, we have shown that some drugs and renal toxins in completely subtoxic doses can make experimental animals predisposed to, or more sensitive to, acute kidney injury,[17–20] with associated risk of chronic renal failure.[27] The relevance of this is that individuals apparently unaffected by a treatment, or exposure to toxins such as tobacco, could unknowingly be predisposed to developing acute kidney injury in certain circumstances (for example, other treatments, radiological contrasts, environmental toxicity) that do not harm non-predisposed individuals. Our group has identified and patented factors associated with this acquired hypersensitivity, and are clinically and technologically developing these as urinary markers.[17–20] The clinical application of these markers will allow us not only to detect predisposition, but

For peer review only

to stratify patients in a preventive and personalized manner, according to their individual acquired risk resulting from apparently innocuous pharmacological treatments or chemical exposures.

In the case of smokers, this hypersensitivity becomes especially relevant, since it could have been acquired by the consumption of the multiple substances contained in tobacco. The possibility of identifying patients at risk could prevent possible acute kidney injury derived from, for example, treatments with potentially nephrotoxic drugs, administration of contrast media, or exposure to substances toxic to the kidney. The appearance of acute damage in this context could be of great importance, since it has been shown that acute kidney injury is a risk factor for the development of chronic kidney disease. Even after initial full recovery of renal function, some patients develop a progressive and persistent deterioration of renal function, and these patients are more likely to progress to end-stage renal disease.[28]

Finally, we also propose to study whether renal parameters and markers are restored with smoking cessation. This fact would consolidate the argument that tobacco is an avoidable risk in the progression and pathology of kidney disease, and also support the benefits of ceasing consumption.

In short, this project addresses two issues of high concern in the health field; smoking and chronic kidney disease. The concept is aimed at finding diagnostic tools for the early detection of tobacco-associated chronic kidney damage, with a preventive method in terms of disease development, and a personalized method regarding each patient's individual hypersensitivity. The tools developed from this project could not only reduce the major economic and social costs associated with kidney disease, but could also act as deterrents to convince patients to stop smoking.

Study limitations

The variables included are biomarkers of early kidney damage and predisposition to acute kidney injury induced by certain renal toxins. It is possible that there are other (unknown) markers with the potential to predict tobacco-associated kidney damage that we have not included in our project.

Ethics approval: The study has been approved by the Clinical Research Ethics Committee (CEIC) of the Health Area of Salamanca (PI05/01/2018, January 16, 2018).

Collaborators: Members of the BIOTAB (Project acronym; Biomarkers of kidney damage and tobacco) Group: Ana Isabel Morales Martín (AIM), Marta Prieto Vicente (MP), Laura Vicente Vicente (LVV), Alfredo Ginés Casanova Paso (AC), María Teresa Hernández Sánchez (THS),

For peer review only

Moisés Pescador Garriel, Ángela de Cabo Laso, Jesús González Sánchez, Natalia Sánchez Aguadero, Carmela Rodríguez Martín, Benigna Sánchez Salgado, Cristina Agudo Conde, Cristina Lugones Sánchez, Manuel Ángel Gómez Marcos (MGM), Luis García Ortiz (LGO), Miguel Ángel Hernández Mezquita, Miguel Barrueco Ferrero.

Author´s Contributions: AIM participated in the conception of the idea for the study. AIM, MP and LVV participated in the design of the study, the development of the protocol and in the writing of the manuscript. AC, THS, MGM and LGO have reviewed the manuscript. The project will be conducted by the BIOTAB group.

Funding: This study was funded by the Spanish Ministry of Science Innovation and Universities (MICINN) and the Carlos III Health Institute/European Regional Development Fund (ERDF) (grant number: PI17/01979, RETICS RD16/0009/0025), and by Fundación Samuel Solórzano (University of Salamanca, Spain), grant number FS/23-2017.

Acknowledgements: Authors would like to thank the patients participating in the project for their selfless collaboration.

Competing interests: None declared.

REFERENCES

1 World Health Organization. WHO report on the global tobacco epidemic 2015: raising taxes on tobacco. 2015.https://apps.who.int/iris/bitstream/handle/10665/178574/9789240694606_eng.pdf;jsessionid=6D7792BC1BD25368F5A92210218E7129?sequence=1 (accessed 4 May 2019).

2 Whelton PK, Perneger TV, He J, *et al.* The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. *J Hum Hypertens* 1996;**10**:683–9.

3 Pinto-Sietsma SJ, Mulder J, Janssen WM, *et al.* Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. *Ann Intern Med* 2000;**133**:585–91. doi:10.7326/0003-4819-133-8-200010170-00008

4 Orth SR. Smoking--a renal risk factor. *Nephron* 2000;**86**:12–26. doi:10.1159/000045708

5 Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. *Nephrol Dial Transplant* 1994;**9**:1097–102. doi:10.1093/ndt/9.8.1097

6 Hammer Y, Cohen E, Levi A, *et al.* The Relationship between Cigarette Smoking and Renal Function: A Large Cohort Study. *Isr Med Assoc J* 2016;**18**:553–6.

7 Stegmayr BG. A study of patients with diabetes mellitus (type 1) and end-stage renal failure: tobacco usage may increase risk of nephropathy and death. *J Intern Med* 1990;**228**:121–4. doi:10.1111/j.1365-2796.1990.tb00204.x

For peer review only

8 Rocco MV, Soucie JM, Reboussin DM, *et al.* Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). *JASN* 1996;**7**:889–96.

9 Vargas M. Documento Marco sobre Enfermedad Renal Crónica (ERC) dentro de la estrategia de Abordaje a la cronicidad en el SNS. Subdirección General De Calidad y Cohesión. Ministerio de Sanidad. Gobierno de España. Consejerías de Sanidad de las CCAA. 2015.https://www.mscbs.gob.es/organizacion/sns/planCalidadSNS/pdf/Enfermedad_Renal_Cronica_2015.pdf (accessed 20 May 2019).

10 Blank MD, Cobb CO, Kilgalen B, *et al.* Acute effects of waterpipe tobacco smoking: a double-blind, placebo-control study. *Drug Alcohol Depend* 2011;**116**:102–9. doi:10.1016/j.drugalcdep.2010.11.026

11 Vaidya VS, Waikar SS, Ferguson MA, *et al.* Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. *Clin Transl Sci* 2008;**1**:200–8. doi:10.1111/j.1752-8062.2008.00053.x

12 Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of Acute Kidney Injury. *Annu Rev Pharmacol Toxicol* 2008;**48**:463–93. doi:10.1146/annurev.pharmtox.48.113006.094615

13 Bonventre JV, Vaidya VS, Schmouder R, *et al.* Next-generation biomarkers for detecting kidney toxicity. *Nat Biotechnol* 2010;**28**:436–40. doi:10.1038/nbt0510-436

14 Zhou Y, Vaidya VS, Brown RP, *et al.* Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. *Toxicol Sci* 2008;**101**:159–70. doi:10.1093/toxsci/kfm260

15 Jungbauer CG, Uecer E, Stadler S, *et al.* N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure. *Nephrology (Carlton)* 2016;**21**:490–8. doi:10.1111/nep.12632

16 Devarajan P. The Use of Targeted Biomarkers for Chronic Kidney Disease. *Adv Chronic Kidney Dis* 2010;**17**:469–79. doi:10.1053/j.ackd.2010.09.002

17 Vicente-Vicente L, Ferreira L, González-Buitrago JM, *et al.* Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats. *Toxicology* 2013;**304**:83–91. doi:10.1016/j.tox.2012.12.006

18 Vicente-Vicente L, Sánchez-Juanes F, García-Sánchez O, *et al.* Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase. *Toxicol Lett* 2015;**234**:99–109. doi:10.1016/j.toxlet.2014.11.033

19 Ferreira L, Quiros Y, Sancho-Martínez SM, *et al.* Urinary levels of regenerating islet-derived protein III β and gelsolin differentiate gentamicin from cisplatin-induced acute kidney injury in rats. *Kidney International* 2011;**79**:518–28. doi:10.1038/ki.2010.439

20 Quiros Y, Ferreira L, Sancho-Martínez SM, *et al.* Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein. *Kidney Int* 2010;**78**:1006–15. doi:10.1038/ki.2010.267

21 World Health Organization. Research for International Tobacco Control. WHO report on the global tobacco epidemic. The MPOWER package. 2008.https://apps.who.int/iris/bitstream/handle/10665/43818/9789241596282_eng.pdf?sequence=1 (accessed 31 May 2019).

For peer review only

22 Gomez-Marcos MA, Martinez-Salgado C, Gonzalez-Sarmiento R, *et al.* Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study. *BMJ Open* 2016;**6**:e011031. doi:10.1136/bmjopen-2016-011031

23 Jaffe M. Ueber den Niederschlag welchen Pikrinsäure in normalen Harn erzeugt und über eine neue reaction des Kreatinins. *Z Physiol Chem* 1886;**10**:391–400.

24 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry* 1976;**72**:248–54. doi:10.1016/0003-2697(76)90527-3

25 Escalante-Gómez C, Zeledón-Sánchez F, Ulate-Montero G. Proteinuria,fisiología y fisiopatología aplicada. *Acta Médica Costarricense* 2007;**49**:83–9.

26 World Medical Association. WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (accessed 15 Apr 2019).

27 Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: From the laboratory to the clinic. *Nephrol Ther* 2016;**12 Suppl 1**:S41-48. doi:10.1016/j.nephro.2016.02.005

28 Le Clef N, Verhulst A, D'Haese PC, *et al.* Unilateral Renal Ischemia-Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice. *PLoS ONE* 2016;**11**:e0152153. doi:10.1371/journal.pone.0152153

FIGURE

Figure 1: Study design outline. Recruitment centers, patients' distribution by groups, proposed objectives, and specific biomarkers for each objective. RF, Risk Factors; NAG, N-acetyl-beta-D-Glucosaminidase; KIM-1, Kidney Injury Molecule-1; NGAL, Neutrophil Gelatinase-Associated Lipocalin; GM2AP, Ganglioside GM2 Activator Protein; CAUSA, University Hospital of Salamanca

For peer review only



90x92mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2019-032918 on 8 March 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.